ABBOTT LABORATORIES

Abbott Laboratories

Medical Devices Healthcare North Chicago, IL, United States ABT (NYQ) Website
Quarter: Q3 2025 Reported: July 17, 2025 Sentiment: Neutral

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company provides pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Stock Performance (90 Days)

Data through Nov 14, 2025
Layoff Events
Earnings Calls

Quick Summary

Abbott Laboratories announced its Q2 2025 results on July 17, 2025, emphasizing its use of non-GAAP financial measures for clearer operational insights. This excerpt did not include specific revenue, earnings, or guidance figures, leaving detailed performance metrics undisclosed.

Sign in for a more detailed summary

Create a free account to access detailed earnings summaries and full transcripts.

Key Highlights

  • Abbott Laboratories announced its Q2 2025 results on July 17, 2025.
  • The company utilizes various non-GAAP financial measures for performance assessment.
  • Non-GAAP measures adjust for unusual items, restructuring, and intangible amortization.
  • Management believes non-GAAP metrics provide useful information for evaluating ongoing business performance.
  • Investors are cautioned to use non-GAAP measures in addition to, not as a substitute for, GAAP.
  • Specific financial results (revenue, earnings, EPS, guidance) were not provided in this excerpt.

Financial Metrics

eps
revenue
guidance
net income

Stock Price

$130.59
ABT· NYQ
1.03%

Company Info

Industry
Medical Devices
Sector
Healthcare
Headquarters
North Chicago, IL, United States
CEO
Mr. Robert B. Ford
Employees
114,000

Layoff Stats

Layoff Events
0
Total Affected
0

Financials

Market Cap $227.08B